[3] Upon returning to North America, Ebert enrolled at Harvard Medical School (HMS) and worked with Frank Bunn, whom he later listed as a major reason for pursuing a career in hematology.
[6] Ebert started his career as a Harvard Medical School faculty member at Brigham and Women’s Hospital, where he led an independent research laboratory and practiced medicine as a hematologist/oncologist.
[8] An independent line of investigation characterized and defined clonal hematopoiesis of indeterminate potential (CHIP) as a precursor state for blood cancers and a risk factor for inflammatory diseases.
In 2018, Ebert, was elected a member of the National Academy of Medicine for his "contributions to understanding the genetics and biology of myeloid malignancies, to the characterization of clonal hematopoiesis, and for elucidating the mechanism of action of thalidomide and its analogs.
[11] He has received multiple recognitions for mentorship including the Thomas McMahon Award and the Seidman Prize from the HST Program at Harvard Medical School.